KMD Bioscience Co., Ltd.
400-621-6806
Service Line：+1-315-239-3085
Address：FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：[email protected]
| Catalog Number | YR1386 |
|---|---|
| Product Name | Anti-Human DLL3 Recombinant Antibody |
| Molecular Name | Rovalpituzumab |
| Alias | Anti-DLL3 Recombinant Antibody, Research Grade Rovalpituzumab |
| CAS Number | 1613313-01-1 |
| Target | DLL3[Homo sapiens] |
| Isotype | IgG1 Kappa |
| Clonity | Monoclonal |
| Source | CHO Cells |
| Size | 1mg, 5mg |
| Concentration | 1mg/ml |
| Purity | >95% as determined by SDS-PAGE |
| Buffer | PBS, pH7.5 |
| Background | Rovalpituzumab tesirine (Rova-T) is an experimental antibody-drug conjugate targeting the protein DLL3 on tumor cells. It was originally developed by Stemcentrx and was purchased by AbbVie. It was tested for use in small-cell lung cancer, but development was terminated after unsuccessful phase III trial. |
| Storage | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
| Note | This product is for research use only. |
FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：[email protected]
Hot Line： +1-315-239-3085
Technical Support：[email protected]
